<DOC>
	<DOCNO>NCT00422903</DOCNO>
	<brief_summary>Evaluate percentage clinical objective response ( cOR ) patient HER2 negative early breast cancer treat pre operative ( neoadjuvant ) lapatinib letrozole</brief_summary>
	<brief_title>Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm infiltrate primary breast cancer 2.0 cm large clinical diameter ER and/or PgR positive cancer ( &gt; 10 % positive cancer cell assess IHC ) Postmenopausal status , define least one following : ≥ 60 year age &lt; 60 year age amenorrheic ≥ 12 month prior day 1 &lt; 60 year age amenorrheic &lt; 12 month prior day , without uterus : luteinizing hormone ( LH ) follicle stimulate hormone ( FSH ) value within postmenopausal range Prior bilateral oophorectomy Prior radiation castration amenorrhea least 6 month HER2 negative tumor ( IHC 02+ , FISH negative ) Availability tumor tissue suitable biological molecular examination start primary treatment Age 18 year ECOG PS 01 Normal organ marrow function define : leukocyte &gt; 3000/mL absolute neutrophil count &gt; 1,500/mL platelet &gt; 100,000/mL total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional upper limit normal Creatinine within normal institutional limit Cardiac ejection fraction within institutional range normal measure echocardiogram MUGA scan . Eligibility patient receive medication substance know affect , potential affect activity pharmacokinetics lapatinib determine follow review use Principal Investigator . A list medication substance know potential interact CYP450 isoenzymes provide Ability understand willingness sign write informed consent document . Ability swallow retain oral medication . Exclusion criterion : Stage IIIB , IIIC , inflammatory breast cancer Stage IV breast cancer Contraindication treatment letrozole Prior treatment chemotherapy , endocrine therapy radiotherapy . Prior treatment EGFR target therapy Treatment investigational agent , herbal ( alternative ) medicine History allergic reaction attribute compound similar chemical biologic composition lapatinib Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement HIVpositive patient receive combination antiretroviral therapy GI tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) Concomitant requirement medication classify CYP3A4 inducer inhibitor ( See section 3.7.4.2 Other concomitant treatment )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>neo-adjuvant</keyword>
	<keyword>letrozole</keyword>
	<keyword>lapatinib</keyword>
	<keyword>primary breast cancer</keyword>
</DOC>